Novel design of dual-action Pt(<scp>iv</scp>) anticancer pro-drugs based on cisplatin and derivatives of the tyrosine kinase inhibitors imatinib and nilotinib-Reference-Cited by-同舟云学术

Novel design of dual-action Pt(iv) anticancer pro-drugs based on cisplatin and derivatives of the tyrosine kinase inhibitors imatinib and nilotinib

Published:2023 Issue:39 Volume:52 Page:14110-14122
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Beirne Darren Fergal¹^ORCID,Farkaš Barbara²,Donati Chiara³,Gandin Valentina³,Rozas Isabel²^ORCID,Velasco-Torrijos Trinidad¹⁴,Montagner Diego¹⁴^ORCID

Affiliation:

1. Department of Chemistry, Maynooth University, Ireland

2. School of Chemistry, Trinity College Dublin, Ireland

3. Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy

4. Kathleen Londsdale Institute for Human Health Research, Maynooth University, Ireland

Abstract

A novel strategy for the development of Pt(IV) cisplatin-based prodrugs with tyrosine kinase inhibitors (TKi's) containing a detailed theoretical approach, synthesis, chemical characterization and preliminary results as anticancer agents and TKi's

Funder

Science Foundation Ireland

Irish Research Council

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/DT/D3DT02030D

Reference65 articles.

1. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias

2. Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

3. World Health Organization Model List of Essential Medicines , World Health Organization, Geneva , 22nd List, 2021 . https://iris.who.int/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf

4. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pt(IV) Prodrug Photoactivation: A Promising Strategy for Cancer Therapy;Current Protein & Peptide Science;2024-12

2. Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs;Journal of Medicinal Chemistry;2024-05-31

3. 2D and 3D anticancer properties of C2-functionalised glucosamine-Pt (IV) prodrugs based on cisplatin scaffold;Frontiers in Chemistry;2024-05-06

4. Design, Synthesis and Biological Evaluation of Novel Phenyl-Substituted Naphthoic Acid Ethyl Ester Derivatives as Strigolactone Receptor Inhibitor;International Journal of Molecular Sciences;2024-03-31

5. Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity—a perspective overview;BioMetals;2023-11-06